专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07132432B2 Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) 有权
标题翻译：海因衍生物作为肿瘤坏死因子-α转化酶（TACE）的抑制剂
公开(公告)号：US07132432B2
公开(公告)日：2006-11-07
申请号：US10858978
申请日：2004-06-02
申请人： Jingwu Duan , Chu-Biao Xue , James Sheppeck , Bin Jiang , Lihua Chen
发明人： Jingwu Duan , Chu-Biao Xue , James Sheppeck , Bin Jiang , Lihua Chen
IPC分类号： A61K31/147 , C07D453/02
CPC分类号： C07D413/04 , C07D413/14
摘要： The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables L, Z0, R1, R4, R5, and R11 are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.
摘要翻译：本发明提供式（I）化合物或其立体异构体或药学上可接受的盐形式，其中变量L，Z 0，R 1，R 2， 4，R 5和R 11定义如本文所定义，其可用作基质金属蛋白酶（MMP），TNF-α转化酶的抑制剂（TACE），软骨聚集蛋白聚糖酶或其组合。

2. 发明申请

US20050176716A1 Modulators of the glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof 有权
标题翻译：糖皮质激素受体，AP-1和/或NF-κB活性的调节剂及其用途
公开(公告)号：US20050176716A1
公开(公告)日：2005-08-11
申请号：US11034652
申请日：2005-01-13
申请人： Jingwu Duan , Bin Jiang , James Sheppeck , John Gilmore
发明人： Jingwu Duan , Bin Jiang , James Sheppeck , John Gilmore
IPC分类号： A01N43/58 , A01N43/60 , A61K31/495 , A61K31/498 , A61K31/50 , C07D241/36 , C07D403/12 , C07D417/02 , C07D417/12 , C07D417/14 , C07D43/02
CPC分类号： C07D403/12 , C07D241/36 , C07D417/12 , C07D417/14
摘要： A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
摘要翻译：提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有式（I）其立体异构体，或其溶剂化物，或其前药，或其药学上可接受的盐，其中Z为CONR 1，R 2或CH 2 > 2个NR 2 R 2，并且其中X 1 -X 4中的至少两个和 /或X 5 -X 8是N或NR 18，R，R a，R SUP R 1，R 2，R 2，R 2，R 2，R 2， > 18 。还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

3. 发明授权

US07625921B2 Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof 有权
标题翻译：糖皮质激素受体，AP-1和/或NF-κB活性的调节剂及其用途
公开(公告)号：US07625921B2
公开(公告)日：2009-12-01
申请号：US11034822
申请日：2005-01-13
申请人： Jingwu Duan , James Sheppeck , Bin Jiang , John L. Gilmore
发明人： Jingwu Duan , James Sheppeck , Bin Jiang , John L. Gilmore
IPC分类号： A61K31/4748 , C07D401/14 , C07D417/12
CPC分类号： C07D471/08 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14
摘要： A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
摘要翻译：提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有式（I）其立体异构体，或其溶剂合物或其前药，或其药学上可接受的盐，其中Z为CONR1R2或CH2NR1R2，并且其中X1-X8中的至少一个为N，R，Ra，Rb， Rc和Rd在本文中定义。还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

4. 发明授权

US07569689B2 Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof 有权
标题翻译：糖皮质激素受体，AP-1和/或NF-κB活性的调节剂及其用途
公开(公告)号：US07569689B2
公开(公告)日：2009-08-04
申请号：US11034652
申请日：2005-01-13
申请人： Jingwu Duan , Bin Jiang , James Sheppeck , John L. Gilmore
发明人： Jingwu Duan , Bin Jiang , James Sheppeck , John L. Gilmore
IPC分类号： A61K31/498 , C07D417/14
CPC分类号： C07D403/12 , C07D241/36 , C07D417/12 , C07D417/14
摘要： A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
摘要翻译：提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有式（I）其立体异构体，或其溶剂合物，或其前药，或其药学上可接受的盐，其中Z为CONR1R2或CH2NR1R2，并且其中X1-X4和/或X5-X8中的至少两个为N或NR18 ，R，R a，R b，R c，R d，R 1，R 2和R 18如本文所定义。还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

5. 发明申请

US20050182082A1 Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof 有权
标题翻译：糖皮质激素受体，AP-1和/或NF-kB活性的调节剂及其用途
公开(公告)号：US20050182082A1
公开(公告)日：2005-08-18
申请号：US11034822
申请日：2005-01-13
申请人： Jingwu Duan , James Sheppeck , Bin Jiang , John Gilmore
发明人： Jingwu Duan , James Sheppeck , Bin Jiang , John Gilmore
IPC分类号： A61K31/439 , A61K31/473 , A61K31/4748 , C07D221/28 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14 , C07D471/08
CPC分类号： C07D471/08 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14
摘要： A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
摘要翻译：提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有式（I）其立体异构体，或其溶剂化物，或其前药，或其药学上可接受的盐，其中Z为CONR 1，R 2或CH 2 > 2 1 2 其中X 1 -X 8中的至少一个为 N和R，R a，O，R b，R c和R d都在本文中定义。还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

6. 发明授权

US07294624B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases 有权
标题翻译：巴比妥酸衍生物作为TNF-α转化酶（TACE）和/或基质金属蛋白酶的抑制剂
公开(公告)号：US07294624B2
公开(公告)日：2007-11-13
申请号：US10321144
申请日：2002-12-17
申请人： Jingwu Duan , Bin Jiang , Lihua Chen , Zhonghui Lu , Joseph Barbosa , William J. Pitts
发明人： Jingwu Duan , Bin Jiang , Lihua Chen , Zhonghui Lu , Joseph Barbosa , William J. Pitts
IPC分类号： A01N43/58 , A61K31/50 , C07D237/00 , C07D239/02
CPC分类号： C07D239/54 , C07D239/62 , C07D239/70 , C07D401/12 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/10 , C07D491/10
摘要： The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, R2, R3, R4, R5, n, W, U, X, Y, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.
摘要翻译：本申请描述了式I的新型巴比妥酸衍生物或其药学上可接受的盐或前药形式，其中A，B，L，R 1，R 2， R 4，R 4，R 5，n，W，U，X，Y，Z，U a，在本说明书中定义，其可用作TNF-α转化酶（TACE）和/或基质金属蛋白酶（MMP）抑制剂。

7. 发明授权

US07595317B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases 有权
标题翻译：巴比妥酸衍生物作为TNF-α转化酶（TACE）和/或基质金属蛋白酶的抑制剂
公开(公告)号：US07595317B2
公开(公告)日：2009-09-29
申请号：US11696847
申请日：2007-04-05
申请人： Jingwu Duan , Bin Jiang , Lihua Chen , Zhonghui Lu , Joseph Barbosa , William J. Pitts
发明人： Jingwu Duan , Bin Jiang , Lihua Chen , Zhonghui Lu , Joseph Barbosa , William J. Pitts
IPC分类号： A01N43/58 , A61K31/50 , C07D237/00 , C07D239/02
CPC分类号： C07D239/54 , C07D239/62 , C07D239/70 , C07D401/12 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/10 , C07D491/10
摘要： The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, R2, R3, R4, R5, n, W, U, X, Y, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.
摘要翻译：本申请描述了式I的新型巴比妥酸衍生物或其药学上可接受的盐或前药形式，其中A，B，L，R 1，R 2，R 3，R 4，R 5，n，W，U，X，Y， Ua，Xa，Ya和Za在本说明书中定义，其可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。

8. 发明申请

US20070167451A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES 有权
标题翻译：作为TNF-α转化酶（TACE）和/或基质金属蛋白酶抑制剂的巴比妥酸衍生物
公开(公告)号：US20070167451A1
公开(公告)日：2007-07-19
申请号：US11696847
申请日：2007-04-05
申请人： Jingwu Duan , Bin Jiang , Lihua Chen , Zhonghui Lu , Joseph Barbosa , William Pitts
发明人： Jingwu Duan , Bin Jiang , Lihua Chen , Zhonghui Lu , Joseph Barbosa , William Pitts
IPC分类号： A61K31/53 , A61K31/517 , A61K31/515 , C07D413/02 , C07D403/02
CPC分类号： C07D239/54 , C07D239/62 , C07D239/70 , C07D401/12 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/10 , C07D491/10
摘要： The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, R2, R3, R4, R5, n, W, U, X, Y, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.
摘要翻译：本申请描述了式I的新型巴比妥酸衍生物或其药学上可接受的盐或前药形式，其中A，B，L，R 1，R 2， R 4，R 4，R 5，n，W，U，X，Y，Z，U a，在本说明书中定义，其可用作TNF-α转化酶（TACE）和/或基质金属蛋白酶（MMP）抑制剂。

9. 发明申请

US20070129400A1 Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof 有权
标题翻译：糖皮质激素受体，AP-1和/或NF-kB活性的调节剂及其用途
公开(公告)号：US20070129400A1
公开(公告)日：2007-06-07
申请号：US11451660
申请日：2006-06-13
申请人： Jingwu Duan , Zhonghui Lu , David Weinstein , Bin Jiang
发明人： Jingwu Duan , Zhonghui Lu , David Weinstein , Bin Jiang
IPC分类号： A61K31/4709 , A61K31/4439 , A61K31/428 , A61K31/427 , A61K31/416 , C07D417/02 , C07D403/02 , C07D405/02 , C07D409/02
CPC分类号： C07D401/04 , C07D231/56 , C07D401/06 , C07D403/04 , C07D405/04 , C07D405/06 , C07D409/06 , C07D417/06 , C07D417/12
摘要： Non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or hydrate thereof, where J is selected from NR1 or C(R4)(R4a); K is selected from NR2 or C(R5)(R5a); L is selected from NR3 or C(R6)(R6a); and A, X, Y, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R8, R10, R11, and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
摘要翻译：提供非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性（包括肥胖症，糖尿病，炎症和免疫疾病）的调节相关的疾病，并且具有式（I）的结构，或其对映异构体，非对映异构体，药学上可接受的盐或水合物，其中J选自NR 1或C（R 4 S 4）（R 4a） / SUB>）; K选自NR 2或C（R 5）（R 5a）; L选自NR 3或C（R 6 S）（R 6a）; 和A，X，Y，R 1，R 2，R 3，R 4，R SUB R 4a，R 5，R 5a，R 6，R 6a，R SUB， R 8，R 11，R 11和n如本文所定义。还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

10. 发明申请

US20110002952A1 FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF 有权
标题翻译： GLUCOCORTICOID受体，AP-1和/或NF-κB活性的融合血管调节剂及其用途
公开(公告)号：US20110002952A1
公开(公告)日：2011-01-06
申请号：US12866270
申请日：2009-02-05
申请人： Jingwu Duan , David S. Weinstein , Bin Jiang
发明人： Jingwu Duan , David S. Weinstein , Bin Jiang
IPC分类号： A61K31/5377 , C07D491/147 , A61K31/4375 , A61K38/26 , A61K38/28 , A61K39/00 , A61P37/00 , A61P29/00 , A61P3/00 , A61P37/06 , A61P19/02 , A61P25/00 , A61P11/06 , A61P1/00 , A61P17/06
CPC分类号： C07D491/147
摘要： Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; -A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B1 and B2 rings are pyridyl rings, wherein the B1 and B2 rings are each fused to the A ring and the B1 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R1, R2, and R4, and the B2 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R3, R7, and R3 71, J2, and J3 are at each occurrence the same or different and are independently -AIQA2-; Q is a bond, O, S, S(0), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3 alkylene, substituted C1-3 alkylene, C24 alkenylene, and substituted C24 alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein.
摘要翻译：提供新的非甾体化合物，其可用于治疗与调节糖皮质激素受体，AP-1和/或NF-κB活性相关的疾病或病症，包括具有结构的代谢和炎症和免疫疾病或病症式（I）的化合物：其对映异构体，非对映异构体或其互变异构体或其前药酯或其药学上可接受的盐，其中：Z是杂环基或杂芳基; -A是5-至8-元碳环或5-至8-元杂环; B1和B2环是吡啶环，其中B1和B2环各自与A环稠合，B1环任选被一至三个相同或不同并且独立地选自R 1，R 2和R 4的基团取代并且B2环任选地被一至三个相同或不同并且独立地选自R3，R7和R371的基团取代，J2和J3在每次出现时相同或不同，并且独立地为-AIQA2- ; Q是键，O，S，S（0）或S（O）2; A1和A2相同或不同，并且在每次出现时独立地选自键，C1-3亚烷基，取代的C1-3亚烷基，C24亚烯基和取代的C24亚烯基，条件是选择A1和A2，使得环A为 5-至8-元碳环或杂环; R1至R11如本文所定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式